Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for October 2007
October 1, 2007
- Vertex Announces Publication of Abstracts for Presentation at 58th AASLD Meeting
- Regeneron Announces Positive Primary Endpoint Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration
- Orexo Shows Positive Results in Completed Comparative Phase III Profile Study of the Sublinox Sleep Aid Involving Insomnia Patients
- ChemGenex Announces Positive Preliminary Data From Phase 2/3 Clinical Trial of Ceflatonin(R) at International Conference
- Addex Pharmaceuticals Announces ADX10061 Phase IIa Smoking Cessation Data
- Theratechnologies Reports Positive 52-Week Phase 3 Results for Its Lead Drug Candidate Tesamorelin
- Webcast Alert: Isis Pharmaceuticals Discusses its New ISIS 301012 Phase 2 Clinical Data Presented at the DALM Symposium
- Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
- Macusight Announces Positive Initial Results from Phase 1 Study of Sirolimus in Diabetic Macular Edema
- ADVENTRX Pharmaceuticals to Report Results from Phase 2b Clinical Trial of ANX-510 (Cofactor)
- MacuSight Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
- FASgen Announces Significant Milestone in Its Cancer Drug Development Program
October 2, 2007
- Vaginal Progesterone Gel May Improve Infant Outcomes and Reduce the Rate of Preterm Birth in Women with a Short Cervix in Mid-Pregnancy
- Adventrx Pharmaceuticals Announces Results From Phase 2b Clinical Trial of ANX-510 (CoFactor)
- NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
- Introgen Announces Publication of Research Showing Promising Activity of INGN 241 Combined with Velcade in Ovarian Cancer
- CardioVascular BioTherapeutics Completes Phase I Wound Healing Trial
- Advanced Life Sciences to Present Data from Selected Cethromycin Clinical Trials at the 45th Annual Meeting of the Infectious Diseases Society of America
- Lu AA21004 Shows Highly Significant Results in Clinical Phase II Trial
- Introgen Announces Publication of Research Showing Activity of INGN 241 Combined with Velcade
- HemoBioTech's CEO, Arthur Bollon, Ph.D., to Present at The NanoTX'07 Conference and Expo
October 3, 2007
- Inspire Announces Poster Presentations at the 2007 North American Cystic Fibrosis Conference
- Threshold to Host Conference Call to Discuss Results From Clinical Presentations at European Cancer Conference (ECCO)
- New Data Reveal Topical Divigel (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
- Upstream Biosciences CEO to Unveil Promising New Approach to Treating Sleeping Sickness at International Trypanosomiasis Conference
- Crucell presents Phase I results rabies antibody cocktail showing safety and ability to protect
- Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
- Carrington Subsidiary DelSite to Present at International Vaccine Conference in Ireland
- Depressed Adolescents Respond Best to Combination Treatment
October 4, 2007
- Early Stage Drug Shows Promise Against Cancer Cells from Young Patients
- Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients
- BioSante Pharmaceuticals To Present Validation Data Required for Development of LibiGel (transdermal testosterone gel) in the Treatment of Female Sexual Dysfunction
- Hollis-Eden Pharmaceuticals Presents Positive Results with Novel Drug Candidate HE3235 in Model of Hormone Independent Prostate Cancer
- Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease
- TB4 Triggers Adult Stem Cells to Form New Blood Vessels and Repair Heart Tissue - Reports U.K. Scientist
- Advaxis' John Rothman to Present Phase I Data at the World Vaccine Congress 2007
- Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
- BioSante Pharmaceuticals To Present Validation Data Required for Development of LibiGel (transdermal testosterone gel) in the Treatment of Female Sexual Dysfunction
- Gilead Announces Detailed Results of Phase III Study of Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
- Salix Announces Statistically Significant Top- Line Results for Second Product Registration Study of Granulated Mesalamine in Ulcerative Colitis
- MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
- Thallion to Present ECO-4601 Human Pharmacokinetic Data at AACR-NCI-EORTC Conference
October 5, 2007
- Isis Reports That ISIS 301012 is Well Tolerated in Patients Treated for Five Or More Months
- Heart Failure Patient Recovers After Cellmedicine Adult Stem Cell Therapy
- Bayhill Therapeutics to Present Positive Data From a Phase IIb Trial of BHT-3009 in Multiple Sclerosis
- Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
- Merck's Investigational CETP-Inhibitor, MK-0859 (anacetrapib), Produced Positive Effects on Lipids with No Observed Blood Pressure Changes in Phase IIb Study
- OXiGENE Reports Positive Interim Results from Phase Ib Zybrestat - Bevacizumab Combination Study in Advanced Solid Tumors
- Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
- Karo Bio Presents Positive KB2115 Phase IIa Proof of Concept Data at Two Major Scientific Meetings
- Merck's Investigational CETP-Inhibitor, MK-0859 (anacetrapib), Produced Positive Effects on Lipids with No Observed Blood Pressure Changes in Phase IIb Study
- New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine's Anti-PS Technology Platform
- Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090
- Interim Results from a New Trial of Cancidas (caspofungin acetate) in Pediatric Patients with Documented Fungal Infections
- PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
- Tryton Medical's Side-Branch Stent Demonstrates Unparalleled 6 Month Angiographic Restenosis Reduction
October 8, 2007
- Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012
- Alnylam Presents First Ever Non-Human Primate Data with an RNAi Therapeutic Targeting PCSK9 Showing Significant and Durable Reductions in LDL Cholesterol Levels
- Hollis-Eden Pharmaceuticals Presents Positive Data Demonstrating HE3286 Provides Benefit in Animal Model of Ulcerative Colitis
- Neupro (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinson's Disease
- Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
- The International Myeloma Foundation Says New Thalidomide Data Confirms Survival Benefits for Older Patients
- American and European Parkinson's Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
- Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
- Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
- Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Leading Medical Experts Call for More Effective Strategies to Address Clostridium difficile-Associated Disease
- Noven Announces Results of Phase 3 Clinical Study of Once-Daily Lithium Product
- Topline Findings from Comparative Analysis of Invega and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
- Metabasis Therapeutics Presents Preclinical Results for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia at the American Thyroid Association's National Meeting
- New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
- 21st World Congress of Dermatology Highlights Clinical Significance of Photodynamic Therapy
- Neupro (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinson's Disease
- MediciNova Will Announce Clinical Results From a Phase IIa Clinical Study for MN-221, a Novel Treatment for Status Asthmaticus, On Tuesday, October 9, 2007 At 3:00 a.m. Eastern Time
October 9, 2007
- Vical Demonstrates Dose-Sparing of Protein-Based H5N1 Influenza Vaccine With Vaxfectin Adjuvant
- New Study by ARIAD Scientists Offers Insights into Design of Small-Molecule Drugs to Treat Drug-Resistant Leukemia
- Sirtris Pharmaceuticals' Oral Drug Candidate SRT501 Shown to be Neuroprotective: Implications for SIRT1 Activation in Neurodegenerative Eye Disorders
- Arpida Presents Additional Data on iclaprim at IDSA
- MediciNova Reports Positive Phase IIa Clinical Study Results for MN-221, a Novel Treatment for Status Asthmaticus
- Arpida Presents Additional Data on Iclaprim at IDSA
- New Publication Report -- Hyperthermia Plus Cisplatin as a Treatment for Recurrent Cervical Carcinoma for Previously Irradiated Patients
- New Data for XL880, XL647 and XL184 to Be Presented at AACR-NCI-EORTC
- orBec Clinical Summary Published in "Expert Opinion on Investigational Drugs"
- Cautious Optimism for New Alzheimer's Medications, Reports the Harvard Mental Health Letter
- One Shot of Gene Therapy Spreads Through Brain in Animal Study
- Amorfix Life Sciences develops two vaccines that extend life in Amyotrophic Lateral Sclerosis (ALS) animal model
- Advaxis, Inc. Phase I/II Results of Lovaxin C in Cervical Cancer Study Released
- Antibody Leads to Repair of Myelin Sheath in Lab Study of Multiple Sclerosis and Related Disorders, Mayo Clinic Study Shows
October 10, 2007
- Applied Biosystems Offers Commentary About Discovery of Increased Genetic Variation in Human Genome
- Kiadis Pharma Announces ATIR Interim Clinical Results
- Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
- AMAG Pharmaceuticals, Inc. Announces Eight Abstracts on Ferumoxytol to Be Presented at Upcoming American Society of Nephrology Meeting
- Emergent BioSolutions' Typhoid Vaccine Candidate Achieves Endpoints in Phase II Clinical Study
- Advitech Announces Positive Preclinical Results for Wound-Healing Application
- Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
- Data Show Vaprisol Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
- Ligand Research Published in Journal of Medicinal Chemistry: LGD-2941 Shows Promise in Treating Muscle and Bone Loss
- Multicenter PolyHeme Trauma Study Presented at the American College of Surgeons 93rd Annual Clinical Congress
October 11, 2007
- Clinical Benefits Demonstrated with Low-Dose Gattex in Phase 3 Short Bowel Syndrome Study
- Pro-Pharmaceuticals Reports 43% Response Rate in Colorectal Trial
- CuraGen Announces Top-Line Phase II Results on Velafermin
- Iomai Chief Scientific Officer Dr. Gregory Glenn Details Development of Travelers' Diarrhea Patch at Keystone Conference
- Pluristem to Present Promising PLX Data for Additional Clinical Indications at Prestigious International Conference on Regenerative Medicine
- Biogen Idec Announces Multiple Sclerosis Franchise and Pipeline Presentations at the European Committee for Treatment and Research of Multiple Sclerosis
- VIVUS Announces Qnexa Abstract Presentation at the 7th International Congress on Coronary Artery Disease
- KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
- Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
- UPDATE: Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
- Nymox Announces New BPH Drug Long Term Follow-up Study Clinical Data Presentation October 20 at American Urological Association Meeting
- Ligand Research Published in Journal of Medicinal Chemistry: LGD-2941 Shows Promise in Treating Muscle and Bone Loss
- Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
- New Tysabri Data to Be Presented at the European Committee for Treatment and Research in Multiple Sclerosis
October 12, 2007
- OctoPlus announces positive Phase IIa efficacy and tolerability results for Locteron in hepatitis C
- BioXell announces positive Phase IIb results for Elocalcitol in Benign Prostatic Hyperplasia
- New Preclinical Data Suggests FTY720 May Repair or Reduce Damage Caused by Multiple Sclerosis Through a Direct Effect in the Brain
- Cougar Biotechnology Presents Positive CB7630 Phase II Data at Prostate Cancer Foundation Scientific Retreat
- Threshold Pharmaceuticals to Stop Enrollment in Clinical Trial
- Resverlogix is Presenting at IAS HDL Workshop
- Long-Term Study Shows Copaxone Significantly Slows Progression of Disability and Reduces Relapse Rates in Patients with Relapsing-Remitting Multiple Sclerosis
- PTC Therapeutics Announces Pharmacokinetic and Safety Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
- Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
- New Data Suggests Progression of Disability at Two Years Predicts Multiple Sclerosis (MS) Disability Progression at Eight Years
- New Preclinical Data Suggests FTY720 May Repair or Reduce Damage Caused by Multiple Sclerosis Through a Direct Effect in the Brain
October 15, 2007
- Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimer's Disease
- BioMS Medical Presents at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- Invega Significantly Reduced Symptoms of Schizophrenia Compared to Seroquel in Acutely Ill, Hospitalized Patients
- Review of Probiotic Trial Research Finds Only Bifantis Able to Claim Efficacy versus Placebo for IBS Symptoms
- Improved Perioperative Blood Pressure Control Associated with Reduced Risk of Kidney Dysfunction in Cardiac Surgery Patients
- Sucampo Pharmaceuticals Presents Data on Cobiprostone at American College of Gastroenterology Annual Scientific Meeting
- Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
- Betaferon Long-term Study Shows That Early Disability in MS Patients Predicts Later Cognitive Decline
- Aloxi Phase 3 Data for Post Operative Nausea and Vomiting (PONV) Presented at the Annual Meeting of the American Society of Anesthesiologists (ASA)
- Antisoma Encouraged by ASA404 Prostate Cancer Data
- Clinical Studies Show Remicade Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
- Leuchemix Announces Publication of Data On Its Lead Cancer Drug Candidate
- Xanthus Presents Data from FLT3 Autoimmune Program Supporting Novel Cell-targeted Mechanism for Disease Attenuation
- BioMS Medical Presents at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- Dynogen's Oral Prokinetic Drug, DDP733, Shown to Reduce Reflux in Phase 1B Study
- Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
- New Analysis of Study Data Shows That Asacol (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
- Vaginal Progesterone is Equally Effective and Results in Lower Miscarriage Rates Than Injectable Progesterone in Infertility Treatment
- New Analyses of Long-Term Lialda (mesalamine) Data Presented at ACG
- Celera and Collaborators Identify a Five-Gene Genetic Risk Score That Predicts Risk of Coronary Heart Disease
- Valdoxan, the First Melatonergic Antidepressant, Confirms its Efficacy in Preventing Relapse Whatever the Severity of the Depression
- Alpharma Presents Positive Results From a Phase 2 Study of the Investigational Abuse-Deterrent Opioid ALO-01
- ACG: Study Finds that Asacol Can Provide Faster Symptom Relief
- Ocera Therapeutics Announces Positive Results with AST-120 in Pouchitis
October 16, 2007
- Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime Sleepiness
- Rigel to Present Research Programs at Scientific Conferences
- Arius Highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
- Data from Three Clinical Trials for Perforomist Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
- Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
- Anesiva Announces Pivotal Phase 3 Trial of Zingo Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
- Evotec Reports Positive Top-Line Results in Phase II Study with EVT 201 in Elderly Insomniacs with Daytime Sleepiness
- Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
- XTENT to Present CUSTOM I and CUSTOM II Trial Data at TCT 2007
- Nereus Pharmaceuticals' NPI-0052 Named One of the Industry's Top Ten Unpartnered Oncology Drug Candidates
- Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
- New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
- New Data Suggests Doctors Might Not Be Considering Depression Symptoms That Are Important to Patients, Such as Pain and Anxiety
- Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
- Fish Get Insomnia, Eyes Wide Open, Say Stanford Sleep Researchers
- New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
- Cimzia Demonstrates Sustained Long-Term Efficacy and Favorable Tolerability in the Treatment of Crohn’s Disease at Stable Doses
- Achillion Reports Safety and Potent Antiviral Activity in Topline Results From Elvucitabine Phase 2 Study in HIV-Infected Patients
- Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
- Webcast Alert: Aastrom Announces Conference Call to Discuss the Results from the U.S. Phase I/II Severe Fracture Trial
- MedImpact Study Highlights Treatment Challenges Among Those Suffering from Hypertension
October 17, 2007
- Organon's Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
- Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Curis Announces Presentation at CHI's ''Discovery on Target: Developing Inhibitors for Promising Drug Targets'' Conference
- Omiganan Phase II Rosacea Study Demonstrates Promising Results
- Alnylam and Collaborators Publish New Pre-clinical Results on RNAi Therapeutics for the Treatment of Huntington's Disease
- Tezampanel, TorreyPines Therapeutics' Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
- Cordis Corporation Announces Clinical Studies and Events at TCT 2007
- Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus Coronary Stent Systems at TCT 2007
- New Mircera Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
- SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
- Pro-Pharmaceuticals Novel Carbohydrate Compounds Reverse Liver Fibrosis in Pre-clinical Studies
- Avalon Pharmaceuticals to Present on Its Beta-catenin and c-Myc Pathway Inhibitor Programs at the AACR-NCI-EORTC 2007 International Conference
- OMRIX Biopharmaceuticals Announces Positive Phase I Results with Fibrin Patch
- Cell Therapeutics, Inc. (CTI) to Sponsor Conference in Italy on Women, Smoke and Lung Cancer
- Accentia Announces Results of Market Survey on Chronic Sinusitis Based on Responses From 750 ENT Specialists
- Scientists Show Monoclonal Antibody Leads to Repair of Myelin Sheath in Laboratory Study of Multiple Sclerosis
- Cordis Corporation Announces Clinical Studies And Events At TCT 2007
- Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
- Aethlon Medical Releases Ebola & Marburg Treatment Report
- Study Finds Anti-Convulsant Drug Decreases Pain, Expedites Movement in Knee Replacement Patients
- Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
- Molecular Biometrics Reports IVF Breakthrough at ASRM
October 18, 2007
- Access Pharmaceuticals to Present Data on ProLindac at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference
- ConjuChem Reports Final Results of PC-DAC: Exendin-4 Phase I/II Multiple-Dose Study for Type 2 Diabetes Confirming Safety and Efficacy at Once-Weekly Dosing
- New Phase III data on Organon's asenapine presented at the 20th Annual European Congress of Neuropsychopharmacology in Vienna.
- Genta Announces Presentation of New Clinical and Preclinical Data on Genasense at AACR-NCI-EORTC 'Targets' Conference
- Molecular Insight Pharmaceuticals, Inc. Announces Positive Results of Azedra Phase 1 Dosimetry Trial for Neuroendocrine Tumors
- Survival Data for Avicena's Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
- Surface Logix SLx-4090 Selected Among Top 10 Most Promising Licensing Candidates In Cardiovascular Disease
- Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
- PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy
- Flamel Technologies Announces Positive Results of a Phase I Trial of FT-105 Basal Insulin versus Lantus
- Orexigen Therapeutics to Present Data on Contrave and Empatic at The Obesity Society's 2007 Annual Scientific Meeting
- Independent Study by Fraunhofer Institute in Germany, Using Pluristem's PLX Cells, Shows Promise in the Treatment of Ischemic Stroke
- Acceleron Pharma's ACE-031 Increases Muscle Mass In a Preclinical Model of Glucocorticoid-induced Muscle Loss
- Antibiotics May Not Help Men's Chronic Pelvic Pain: Harvard Doctors Discuss Alternatives
- Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference
- Abbott Scientists Create One Molecule With Two Antibody Functions
- Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Experts Discuss the Efficacy of the Most Recent Treatments Available for Psoriasis
- Japan Institute of Infectious Diseases Publishes Article on Ampligen as Avian Flu Vaccine Immune Enhancer
- St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory
- Oral Drug Restores Missing Protein in Boys With MD
- Immunomedics to Present At the AACR-NCI-EORTC International Conference
- SemBioSys confirms commercially viable levels of Native APO AI in safflower
October 19, 2007
- VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta at AACR-NCI-EORTC International Meeting
- Actelion Announces Multiple Presentations on Tracleer and the REVEAL Registry at CHEST 2007
- MediciNova Reports Phase IIa Clinical Study Results for MN-305, a Treatment for Insomnia
- Pivotal Mircera Study First to Convert Dialysis Patients From Frequent Dosing Directly to Once Every Two Weeks or Once Every Four Weeks
- Data Show Obagi Medical Products' Solubilized Benzoyl Peroxide Gel May Provide Dramatic Reductions in Acne Lesions Within Four Weeks
- PAION Sees Continued Development Rationale for Desmoteplase Based on Findings from Phase III Analysis
October 22, 2007
- XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
- Results of Pre-Clinical Investigation of Ceragenix's Developmental Antibiotic to Prevent Sepsis Presented at International Scientific Meeting
- Arrive Registry Analysis Demonstrates Continued Safety and Efficacy of Taxus Stent in Complex Real-World Patients
- BiPar Announces Upcoming Data Presentations Demonstrating Progress on PARP Inhibitor Drug Pipeline for Cancer
- Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
- Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study
- OREXIGEN(TM) Therapeutics Reports Detailed Results of Phase IIb Trial of Empatic(TM) to Treat Obesity
- Orexigen Therapeutics Reports a Summary of Results from the Phase IIb Trial of Contrave to Treat Obesity
- Can-Fite: CF102 Drug is Effective in Promoting Liver Tissue Regeneration; Clinical Trials with CF102 in the Treatment of Liver Cancer are Due to Commence in Early 2008
- Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
- Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeich's Genous(TM) Bio-engineered R Stent and Boston Scientific's Taxus Stent in Patients at High Risk of Restenosis
- Boston Scientific Promus and Taxus Stents Continue Strong Performance in Safety and Efficacy Measures
- Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome
- Abbott's Xience V Everolimus Eluting Coronary Stent Shows Continued Superiority to Taxus Stent in Reducing Major Adverse Cardiac Events in Spirit III Clinical Trial
- Elixir Medical Announces Positive Clinical Results for the Company's First Drug Eluting Coronary Stent
- Study Using PARI Nebulizer Finds COPD Therapy of Nebulizer and Inhaler Combo More Effective than Inhaler Alone
- Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting
- Positive Five-Year Safety Data for Taxus Stent Reported in Boston Scientific Trial
October 23, 2007
- Micromet is Presenting Four Posters on BiTE Antibodies at the International AACR-NCI-EORTC Conference
- NanoViricides, Inc. Presents at the Global Pharma R&D Summit
- Abbott Announces Positive One-Year Results from the World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
- Orexigen Therapeutics Reports Preclinical Results Showing Contrave Acts on Specific Pathways in the Brain to Reduce Food Intake
- Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
- Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
- EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
- Genasense Can be Administered by Brief High-Dose IV Infusion
- Avalon Pharmaceuticals Announces Its Proprietary Drug Discovery and Development Platform AvalonRx(R) Identifies Potent Selective Inhibitors for the c-Myc and Beta-catenin Pathways
- Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
- Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
- Arius Announces Cancer Stem Cell Antibody Program Successfully Completes First Toxicology Study
- Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
- Progen Presents Preclinical Data for Second-Generation Anti-Tumor Compounds at AACR-NCI-EORTC International Conference
- Copaxone Significantly Decreases Disease Activity in Patients Who Switched from Interferon Beta (INFb) Due to Development of Neutralizing Antibodies (NAbs)
- VIVUS Announces Qnexa Quality of Life Data at the Obesity Society's 2007 Annual Scientific Meeting
- Sunesis Pharmaceuticals Hosts Conference Call to Discuss Preliminary SNS-595 Activity in its Ovarian Cancer Clinical Trial Being Reported at the AACR-NCI-EORTC International Conference
- Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams
- ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar
- InVitria's Animal Free Lacromin Provides a Cost-Effective Improvement Over Transferrin
- Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
- Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
- Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Cleviprex (Clevidipine Butyrate) Rapidly Reduced Blood Pressure and Maintained Control in Study of Patients with Acute Hypertension
October 24, 2007
- ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting
- Spectrum Pharmaceuticals Announces Presentation of SPI-1620 Data at the AACR-NCI-EORTC International Conference
- Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
- Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
- EntreMed Presents Results for Panzem NCD Phase 2 Ovarian Cancer Study
- Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
- Tranzyme Pharma's Motilin Antagonist TZP-201 Shows Potential for Preventing and Treating Chemotherapy-Induced Diarrhea (CID)
- Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination Reolysin and Radiation Clinical Trial
- First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
- OSI Pharmaceuticals Summarizes Data Presented on OSI-906 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Phase I Results Announced for R1507 From Genmab's Collaboration With Roche
- Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
- New Data May Help Guide the Clinical Development of Biomira's PX-478 and PX-866
- Genasense Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
- CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007
- Updated Phase 1 Data for Exelixis' XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
- Tracleer Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
- Access Pharmaceuticals Announces Presentation on ProLindac Phase 2 Study at AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference
- Cephalon Announces Positive Results from Its Pivotal Study of Treanda in Patients with Non-Hodgkin's Lymphoma
- New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with Ambien CR (zolpidem tartrate extended-release) Tablets CIV
- Gilead Announces New Letairis (ambrisentan) Data for the Treatment of Patients with Pulmonary Arterial Hypertension (WHO Group 1)
- Ascenta Therapeutics Highlights Multiple Data Presentations at This Week's AACR-NCI-EORTC International Conference in San Francisco
- Gemin X Presents Mechanism of Action of GMX1778 and Preclinical Data of its Prodrug GMX1777
- Gemin X Identifies Molecules that Inhibit Telomere Maintenance Proteins Important to Cancer Cell Survival
- Angiomax / Angiox (bivalirudin) Significantly Improved Net Outcomes in Heart Attack Patients
- Inhaled Steriods Used as Preventive Treatment Post 9/11
- Nymox Announces Clinical Study Presentation on New BPH Drug at Upcoming American Urological Association Meeting
- Safety Profile of Medtronic's Endeavor Drug-Eluting Stent Affirmed in Comprehensive Data Analysis
- Active Biotech's Cancer Project ANYARA Proven Safe in Combination with Taxotere
- Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
- Drug Eluting Balloons Show Promise as a Potential Alternative to Drug Eluting Stents Used in the Treatment of Coronary Artery Disease
- New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
- BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
- Stanford/Packard Researchers Find Disease Genes Hidden in Discarded Data
October 25, 2007
- Two Clinical Trials for Nebulized Formoterol Fumarate on Long-Term and Cardiovascular Safety in Treating COPD
- SuperGen's Novel Hypomethylating Agent Highlighted at AACR Plenary Session
- DiaKine Therapeutics' Anti-Diabetes Drug Featured in U.S. Research Report
- Synta Presents New Data on Elesclomol (Formerly STA-4783) at AACR-NCI-EORTC International Conference
- Bionovo to Present Mechanism of Action Data Regarding BZL101, Its Anti-cancer Agent, at the American Association of Cancer Research Conference
- Interim Phase 2 Data for Exelixis' XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
- Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
- Unigene Reports Successful Completion of Oral Calcitonin Human Study
- ImmunoGen, Inc. Reports New Clinical and Preclinical Data at AACR-NCI-EORTC
- Seattle Genetics Reports Preclinical Data on SGN-40 and an Anti-CD19 Antibody-Drug Conjugate
- Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
- Avalon Pharmaceuticals Announces Beta-catenin Pathway Inhibitors Demonstrate Significant Tumor Growth Inhibition
- OXiGENE Reports OXi4503 Phase I Interim Data; Mechanism-of-Action Data Published in Peer-Review Journal
- Array BioPharma Reports Positive New Data on ErbB-2 / EGFR Inhibitor, ARRY-543
- CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
- Arqule Announces Clinical and Pre-Clinical Data on Anti-Metastatic Potential of ARQ 197, a Selective c-Met Inhibitor
- Curis Announces Presentation at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Intradigm Study Shows Ability of siRNAs Systemically Delivered With TargeTran System to Suppress Tumor-Induced Angiogenesis in Mice
- Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
- Study Showed Patients Using Copaxone Had Significantly Lower Risk of Relapse and Lower Medical Costs Compared to Patients Using Rebif in Relapsing-Remitting Multiple Sclerosis (RRMS)
- Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD
- New Long-Term Analysis of Clinical Treatment Outcomes Demonstrated Copaxone is More Cost Effective Than Tysabri for Treatment of Relapsing-Remitting Multiple Sclerosis
- Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
- Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Synergy with DNA Damaging Agents
- Advanced Cell Presents Phase I(b) Data Demonstrating Safety and Optimal Dosage for Myoblast Program at TCT Conference and Exposition
- Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Trofex Prostate Cancer Data at AACR
- EntreMed Reports Phase 1 PK and Preclinical Efficacy Results for ENMD-1198
- Novel Alternative Approach to Inhibiting Insulin Growth Factor (IGF) May Provide New Treatment for Breast Cancer and Other Cancers
- Brovana Inhalation Solution Study Data Presented at American College of Chest Physicians Annual Conference
- Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
- Aradigm Corporation Reports Initial Human Data on a Novel Approach to Treatment of Tobacco Smoking Addiction Using its AERx Essence Nicotine Inhaler
- Flamel Technologies Announces Positive Top Line Results of a Clinical Trial of IFN-alpha-XL versus PegIntron in Patients with Chronic Hepatitis C Virus Infection
- Study Shows Vaprisol is Effective in Increasing Serum Sodium Levels and Well-Tolerated in Patients With Euvolemic or Hypervolemic Hyponatremia
- Results of Vyvanse (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
- Final Gemini Study Results Confirm Boosted Invirase Was as Effective as Kaletra While Providing an Improved Triglyceride Profile for HIV Patients
- Advanced Cell Presents Phase I(b) Data Demonstrating Safety and Optimal Dosage for Myoblast Program at TCT Conference and Exposition
- Arius Announces New Findings in Trop-2 and CD59 CANCER Antibody Programs
- EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
- Long-Term 12-Month Safety Data Presented on ADHD Patch Daytrana (methylphenidate transdermal system)
- ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
- BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
- Clinical and Preclinical Data for Oral Indibulin (ZIO-301) Presented at AACR/NCI/EORTC Conference
October 26, 2007
- IDM Pharma Announces Upcoming Clinical Data Presentations
- LifeCycle Pharma Announces Positive Interim Phase II Clinical Trial Results for LCP-Tacro, an Immunosuppressant for the Treatment of Kidney Transplant Patients
- Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
- Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
- CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
- Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
- Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
- Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
- Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine in Glioma Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Data Support Use of SuperGen's CLIMB Technology in Lead Development and Optimization
- CombinatoRx Publishes Clinical Study Results of CRx-102 in Hand Osteoarthritis
- Panacos Announces Greater than 1 Log10 Mean Reduction in 300 mg Bevirimat Cohort
- Celator Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
- Two New Research Papers Published on Thymosin Beta 4
- Celator Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
- AVI BioPharma Announces Partner Breakfast Symposium at 2007 Transcatheter Cardiovascular Therapeutics Conference
- Targacept Scientists to Present at the 37th Annual Meeting of the Society for Neuroscience
- Obesity-Related Hormone is Higher in Children with Down Syndrome
- New Study of Concerta Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
- SemBioSys to Present Insulin Data at the Seventh Annual Diabetes Technology Meeting
October 29, 2007
- BioLineRx Announces Positive Results From Phase 2a Interim Trial Analysis of BL-1020 for the Treatment of Patients With Schizophrenia
- Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
- Results Of Vyvanse (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
- Preclinical Efficacy Data Demonstrate Ability of Tengion's Neo-Bladder Augment to Restore Bladder Function
- Gilead Announces 48-Week Data Evaluating Switching from Combivir To Truvada Among Virologically-Suppressed HIV Patients
- MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
- Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference
- BEYOND study: Results do not support regulatory filing for Betaferon 500 mcg
- EPIX Pharmaceuticals Reports Preliminary Findings from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate
- MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
- Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
- Peptech Successfully Completes Phase I Trial for PN0621
- Addex Presents ADX10059 GERD Data at Conference
- Large Controlled Trial of Widely Used Mood Stabilizers Demonstrates Efficacy in Pediatric Bipolar Disorder
- Cytokine Announces Oral Efficacy of Anti-Cytokine Semapimod
- BioAlliance Pharma's New Entity, AMEP, Shows Anti-angiogenic and Antiproliferative Activity In Vitro and In Vivo
- Scientists Unveil Structure of Molecular Target of Many Drugs
October 30, 2007
- Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
- Significant New Data on Roche's Pegasys and Hepatitis C Pipeline Compounds to be Featured at 58th Annual AASLD Meeting
- Altea Therapeutics Announces Positive Clinical Results for its Basal Insulin Transdermal Patch in Patients with Type 1 Diabetes
- Affymax Highlights Upcoming Hematide Data Presentations at the American Society of Nephrology Renal Week 2007
- Enzon Provides New Data on Customized Linker Technology
- Alfacell's Onconase Shows Promise as Radiation Sensitizer for Lung Cancer Treatment
- Schering-Plough Highlights PEGINTRON Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
- Pittsburgh Based Associates in Ophthalmology Announces New Treatments for Patients Suffering from Macular Degeneration
- One in Seven Americans Age 71 and Older Has Some Type of Dementia, NIH-Funded Study Estimates
- Scientists Use Shared Genome Data To Confirm SORL1 Gene Linked to Alzheimer's
- Superior Remission Rates for Once Daily use of Pentasa (mesalazine) in Ulcerative Colitis
- Misconceptions About Bipolar Disorder Explained, From the Harvard Health Letter
October 31, 2007
- La Jolla Pharmaceutical Company to Present March 2007 Riquent Interim Antibody Data at Two Leading Medical Meetings
- Collegium Pharmaceutical Inc. Announces Successful Completion of Proof of Concept Study for its Abuse Deterrent Sustained Release Opioid Product
- Revotar Reports First Positive Clinical Results From Phase IIa Study in COPD
- Encouraging Preliminary Data from TNFerade Phase II Rectal Cancer Study Presented at ASTRO Meeting
- GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial
- Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
- La Jolla Pharmaceutical Company to Present March 2007 Riquent Interim Antibody Data at Two Leading Medical Meetings
- Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
- Hythiam to Announce Urschel Double-Blind Placebo-Controlled Study Results on Thursday, November 1st
- Lilly Sets Date and Time for American Heart Association Conference Call
- Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
- Santhera Reports Encouraging, First Data from Phase IIa Clinical Trial with SNT-MC17 in Duchenne Muscular Dystrophy
- Vanda Pharmaceuticals' VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
